"The highly lucrative prescription market for hair loss treatments currently does not serve the needs of many patients. Regulatory approval, plus our patent-pending technology would expand our leadership position in hair loss therapies," stated DS Healthcare President and CEO Daniel Khesin.
"We believe our proprietary treatment offers unique benefits that may result in greater efficacy without the undesirable side effects of other prescription hair loss drugs on the market today. Currently there are only two applications approved by the FDA for hair loss. One is an oral tablet and the other is a topical treatment," Khesin added.
DS Healthcare Group Inc. develops biotechnology for topical, and nutritional therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, and salons. Its brands include DS Laboratories (www.DSLaboratories.com), Sigma Skin (www.SigmaSkin.com), Polaris Research Laboratories (www.PolarisReserachLabs.com) and The Pure Guild (www.ThePureGuild.com).